Dow Jones

39,512.84

0.32%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

XLRN

Acceleron Pharma (XLRN)

Acceleron Pharma Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLRN

1 2 3 4 5 6 7 8 9 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
02/12/2021	08:01	Edgar (US Regulatory)	Termination of Registration of a Class of Security Under Section 12(b) (15-12b)	NASDAQ:XLRN	Acceleron Pharma Inc
24/11/2021	14:48	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:XLRN	Acceleron Pharma Inc
23/11/2021	04:21	TipRanks	Merck Completes Acquisition of Acceleron Pharma	NASDAQ:XLRN	Acceleron Pharma Inc
22/11/2021	08:13	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XLRN	Acceleron Pharma Inc
22/11/2021	07:52	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XLRN	Acceleron Pharma Inc
22/11/2021	06:02	Edgar (US Regulatory)	Amended Tender Offer Statement by Third Party (sc To-t/a)	NASDAQ:XLRN	Acceleron Pharma Inc
17/11/2021	13:26	Business Wire	Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck’s Inadequate Offer	NASDAQ:XLRN	Acceleron Pharma Inc
17/11/2021	06:01	Edgar (US Regulatory)	Amended Statement of Ownership: Solicitation (sc 14d9/a)	NASDAQ:XLRN	Acceleron Pharma Inc
09/11/2021	16:31	Business Wire	Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer	NASDAQ:XLRN	Acceleron Pharma Inc
04/11/2021	15:14	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XLRN	Acceleron Pharma Inc
04/11/2021	15:01	Business Wire	Acceleron Reports Third Quarter 2021 Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
28/10/2021	07:00	Business Wire	Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders	NASDAQ:XLRN	Acceleron Pharma Inc
27/10/2021	06:10	Business Wire	Acceleron Announces Third Quarter 2021 REBLOZYL® Net Sales	NASDAQ:XLRN	Acceleron Pharma Inc
25/10/2021	08:17	TipRanks	Acceleron Temptation: Will Shareholders Accept Merck’s Offer?	NASDAQ:XLRN	Acceleron Pharma Inc
20/10/2021	12:58	Edgar (US Regulatory)	Statement of Ownership: Solicitation (sc 14d9)	NASDAQ:XLRN	Acceleron Pharma Inc
12/10/2021	08:26	Edgar (US Regulatory)	Tender Offer Statement by Third Party (sc To-t)	NASDAQ:XLRN	Acceleron Pharma Inc
05/10/2021	11:31	Edgar (US Regulatory)	Statement of Beneficial Ownership (sc 13d)	NASDAQ:XLRN	Acceleron Pharma Inc
01/10/2021	15:17	Edgar (US Regulatory)	Written Communication Relating to an Issuer or Third Party (sc To-c)	NASDAQ:XLRN	Acceleron Pharma Inc
30/09/2021	15:31	Edgar (US Regulatory)	Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)	NASDAQ:XLRN	Acceleron Pharma Inc
30/09/2021	14:52	Business Wire	Avoro Capital Believes Proposed Acquisition of Acceleron Pharma by Merck Undervalues Acceleron Pharma	NASDAQ:XLRN	Acceleron Pharma Inc
30/09/2021	06:34	Dow Jones News	Merck to Buy Acceleron Pharma for $11.5 Billion	NASDAQ:XLRN	Acceleron Pharma Inc
05/08/2021	15:01	Business Wire	Acceleron Reports Second Quarter 2021 Financial Results	NASDAQ:XLRN	Acceleron Pharma Inc
28/07/2021	06:10	Business Wire	Acceleron Announces Second Quarter 2021 REBLOZYL® Net Sales	NASDAQ:XLRN	Acceleron Pharma Inc
26/07/2021	06:00	Business Wire	Acceleron to Webcast Second Quarter 2021 Financial Results on August 5, 2021	NASDAQ:XLRN	Acceleron Pharma Inc
11/06/2021	02:00	Business Wire	Bristol Myers Squibb & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults ...	NASDAQ:XLRN	Acceleron Pharma Inc
08/06/2021	06:00	Business Wire	Acceleron to Host Virtual Research and Development (R&D) Day on June 22, 2021	NASDAQ:XLRN	Acceleron Pharma Inc
19/05/2021	07:00	Business Wire	Acceleron Presents Preliminary Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at...	NASDAQ:XLRN	Acceleron Pharma Inc
19/05/2021	07:00	Business Wire	Acceleron Presents Interim Results from the Open-label Extension of the PULSAR Phase 2 Trial of Sotatercept in Patients with ...	NASDAQ:XLRN	Acceleron Pharma Inc
12/05/2021	09:57	Business Wire	Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congr...	NASDAQ:XLRN	Acceleron Pharma Inc
11/05/2021	06:00	Business Wire	Acceleron to Host Conference Call & Webcast to Review Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pul...	NASDAQ:XLRN	Acceleron Pharma Inc